Overview
Balance Sheet
Cash Flow
Growth Analysis
2023
2022
2021
2020
2019
Profitability Metrics
Gross Margin
46.44%
Operating Margin
108.91%
Net Margin
95.75%
Efficiency Metrics
Revenue per Expense Ratio
1.00
R&D as % of Revenue
0.00%
Earnings Quality
EBITDA Margin
108.91%
Income Tax Rate
0.00%
EPS
2.3800000000
Balance Sheet Analysis
Current Ratio
37.95
Cash Ratio
1.95
Working Capital
$409.43M
Debt to Equity
0.36
Debt to Assets
25.61%
Equity Ratio
71.34%
Cash Flow Analysis
Operating Cash Flow Ratio
52.94%
Free Cash Flow Ratio
52.94%
CapEx to Revenue
0.00%
Dividends Paid
$28.76M
Stock Buybacks
No buybacks
Total Shareholder Returns
$28.76M
Cash Position Change
106.90%
Key Takeaways (2023 FY)
Maintained positive net income growth despite revenue changes
Increased dividend payments by 13.10%
Detailed Growth Metrics
Core Performance
Revenue
209.31%
Net Income
201.04%
EPS
201.28%
Operating Income
221.47%
Operational Efficiency
R&D Expenses
0.00%
SG&A Expenses
3.30%
Operating Cash Flow
-26.49%
Free Cash Flow
-26.49%
Balance Sheet Health
Assets
7.07%
Debt
0.92%
Book Value per Share
6.62%
Inventory
-100.00%
Shareholder Returns
Dividends per Share
13.10%
Shares Outstanding
0.00%
Long Term Trends
3Y Revenue/Share
1,183.05%
5Y Revenue/Share
440.11%
3Y Dividend/Share
-5.55%
5Y Dividend/Share
-20.08%